HCC Combination Therapy Targeting LAG-3, PD-1, and Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for hepatocellular carcinoma (HCC) provide modest benefits with significant adverse effects and high economic costs, and only a portion of patients derive substantial benefit from sorafenib, a multitargeted tyrosine kinase inhibitor.
Innovation Solution
A combination therapy involving a LAG-3 antagonist, a PD-1 pathway inhibitor, and an anti-angiogenesis agent, specifically using antibodies with defined CDR sequences and doses, is administered to treat HCC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If sorafenib is used as monotherapy for HCC, then treatment is simplified and cost is reduced, but treatment efficacy is insufficient and adverse effects remain significant
Solution Approach 1:
The patent combines three different therapeutic agents (LAG-3 antagonist antibody, PD-1 pathway inhibitor antibody, and anti-angiogenesis agent) into a single therapy regimen. This combination approach addresses the technical contradiction by merging multiple effective treatments to enhance overall efficacy while managing complexity through a unified protocol structure.
2Reliability
If combination therapy with multiple agents is used, then treatment efficacy and survival outcomes are improved, but therapy complexity and economic cost increase
Solution Approach 1:
The combination therapy is segmented into three distinct therapeutic components, each targeting different pathways (LAG-3, PD-1, and angiogenesis). This segmentation allows for modular administration and monitoring, managing the complexity of combination therapy by breaking it down into manageable, identifiable components with specific roles.
3Productivity
If sorafenib is administered, then tumor growth is inhibited to some extent, but objective response rate remains low and relapse occurs
Solution Approach 1:
The patent changes the therapeutic parameters by switching from a single-agent TKI approach to a multi-target combination therapy. This parameter change involves altering the mechanism of action, target specificity, and dosage regimen to achieve superior objective response rates and prevent relapse while maintaining tumor growth inhibition.
Data Source
AI summary
The disclosure provides a method of treating a hepatocellular carcinoma with a combination of a LAG-3 antagonist, a PD-1 pathway inhibitor, and an anti-angiogenesis agent.